China
Africa
Explore chapters and articles related to this topic
Medicinal Mushrooms
Published in Anil K. Sharma, Raj K. Keservani, Surya Prakash Gautam, Herbal Product Development, 2020
Temitope A. Oyedepo, Adetoun E. Morakinyo
AHCC is an extract prepared from co-cultured mycelia of several species of Basidiomycete mushrooms through enzyme fermentation (Kidd, 2000; Ritz et al., 2006). AHCC contains polysaccharides, amino acids, and minerals (Figure 7.3), and is available orally. The predominant bioactive components of AHCC are oligosaccharides which constitute about 74% of the total dry weight, out of which 20% are partially acetylated α-1,4-glucans. The glucans in AHCC have low molecular weight of around 5000 daltons (Kidd, 2000). Both of these attributes are peculiar for immunoactive mushroom glucans (Gao et al., 2006; Kamiyama et al., 2013).
Targeting SOX2 in anticancer therapy
Published in Expert Opinion on Therapeutic Targets, 2018
Laura Hüser, Daniel Novak, Viktor Umansky, Peter Altevogt, Jochen Utikal
Moreover, since it was demonstrated that SOX2 is involved in the regulation of cancer features like migration and invasion in breast cancer by the SOX2/miR-181a-5p, miR-30e-5p/TUSC3 axis, it was suggested to target this axis [31]. Zhao et al. [74] showed that expression of miR-126 is low in hepatocellular carcinoma and that a restoration of miR-126 expression results in apoptosis and inhibition of proliferation and cell cycle progression. They also demonstrated that SOX2 was a target of miR-126 and that SOX2 overexpression could partially reverse the effects of miR-126. It was concluded that miR-126 might serve as a therapeutic target since it acts as tumor suppressor partially by targeting SOX2. Active hexose-correlated compound (AHCC) was found to target specifically SOX2 in pancreatic cancer. It was proposed that AHCC might be a candidate for combinatorial anticancer therapy [75].
Active Hexose Correlated Compound (AHCC) Inhibits the Proliferation of Ovarian Cancer Cells by Suppressing Signal Transducer and Activator of Transcription 3 (STAT3) Activation
Published in Nutrition and Cancer, 2018
Jin Young Choi, Seul Lee, Sun-Mi Yun, Dong Hoon Suh, Kidong Kim, Jae Hong No, Eun-Hwan Jeong, Yong Beom Kim
Various natural agents derived from natural sources have been reported to have anticancer effects both in vitro and in vivo (4–7). Active hexose correlated compound (AHCC) is a mixture of polysaccharides, amino acids, lipids, and minerals derived from the culture of the basidiomycete mushroom, Lentinula edodes. AHCC has been reported to have immunomodulatory effects and anticancer effects in various cancers, including head and neck, liver, lung, ovarian, colorectal, and hematologic, in addition to alleviating the side effects associated with chemotherapy (8–13). However, the associated mechanisms of these effects have not been clearly identified.
Efficacy of Lentinula edodes Mycelia Extract on Chemotherapy-Related Tasted Disorders in Pancreatic Cancer Patients
Published in Nutrition and Cancer, 2022
Hiroaki Yanagimoto, Satoshi Hirooka, Tomohisa Yamamoto, So Yamaki, Mitsugu Sekimoto
A standardized extract of cultured Lentinula edodes mycelia, AHCC®, is one of the functional foods used most frequently in cancer patients in clinical practice (2). The most abundant component of AHCC® is oligosaccharides, which account for about 74% of the dry weight. About 20% of the oligosaccharides in AHCC® are α-1,4-glucans, a proportion of which are partially acylated. This extract is produced by the Amino Up Co., Ltd. (Sapporo, Japan) under the trademark “AHCC®.”